Spero Therapeutics SPRO 深 沪
等待开盘 11-06 09:30:00 美东时间
2.43
+0.080
+3.40%
华盛通- 最 高2.48
- 今 开2.35
- 成交量 59.63万股
- 最 低 2.35
- 昨 收 2.35
- 总市值 1.36亿
- 52周最高 3.22
- 市盈率 静 --
- 换手率 1.07%
- 52周最低 0.5052
- 委 比 86.78%
- 总股本 5591.06万
- 历史最高 23.639
- 量 比 1.24
- 振 幅 5.53%
- 历史最低 0.5052
- 每 手 1
- 风险率 0.77%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025
Spero Therapeutics, a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, announced it will release its third quarter 2025 financial results and provide a business update on November 13 after market close. The company does not plan to host a conference call.
11-04 21:05
Spero Therapeutics And GSK Phase 3 PIVOT-PO Data Show Tebipenem Hydrobromide's Potential As The First Oral Carbapenem Antibiotic For Complicated Urinary Tract Infections
Data presented at IDWeek 2025 after study stopped early for efficacyPrimary endpoint met, demonstrating non-inferiority of oral tebipenem HBr compared to intravenous treatment1Data will be shared with regulatory
10-21 14:14
PIVOT-PO Phase 3 Data Show Tebipenem HBr’s Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)
Spero Therapeutics and GSK announced positive phase 3 results for oral tebipenem HBr in treating complicated urinary tract infections (cUTIs), showing non-inferiority to IV imipenem-cilastatin. The trial met its primary endpoint with tebipenem achieving a 58.5% success rate vs 60.2% for IV treatment, with comparable safety profiles. Data were presented at IDWeek 2025 and will support regulatory filings. If approved, tebipenem HBr would be the fir...
10-21 06:00
Genmab Reports $3.67B in DARZALEX Worldwide Sales for Q3 2025
Genmab A/S (NASDAQ:GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX
10-14 18:26
Spero Therapeutics Announces Presentations on Tebipenem Hbr at IDWeek
Spero Therapeutics will present tebipenem HBr study results at IDWeek 2025, highlighting its Phase 3 trial success for treating complicated urinary tract infections. The oral presentation and posters will discuss efficacy, safety, and in vitro activity against bacterial infections. Tebipenem HBr, an oral carbapenem, has received FDA designations and is being developed with GSK. The presentation will take place on October 20 and 21 in Atlanta.
10-14 12:00
Red Cat Collaborates with Safe Pro Group to Embed Real-Time AI-Powered Threat Detection Onboard the Black Widow™ Drone Platform
Red Cat Holdings, Inc. and Safe Pro Group Inc. announce a strategic collaboration to integrate Safe Pro's AI-powered threat detection technology into Red Cat's Black Widow drones. This integration enhances the drones' ability to detect explosive threats in real-time, improving situational awareness and decision-making for military operations. The collaboration leverages Safe Pro's advanced systems to process drone imagery and share critical data,...
09-15 12:00
Perspective Therapeutics Names Joel Sendek CFO As Juan Graham Departs
Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced the appointment of Joel Sendek as
09-04 19:24
Spero Therapeutics Q2 EPS $(0.03) Beats $(0.38) Estimate, Sales $14.189M Up From $10.197M YoY
Spero Therapeutics (NASDAQ:SPRO) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.38) by 92.11 percent. This is a 90.91 percent increase over losses of $(0.33) per share
08-13 04:03
Here are the major earnings after the close Tuesday
Major earnings expected after the bell on Tuesday include: CoreWeave (CRWV) Inovio Pharmaceuticals (INO) Luminar Technologies (LAZR) Lumentum Holdings (LITE) Gladstone Investment Corporation (GAIN) Ot...
08-12 22:00
Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update
Spero Therapeutics announced the early termination of its Phase 3 PIVOT-PO trial for tebipenem HBr in treating complicated urinary tract infections (cUTI) due to demonstrated efficacy. The company plans to submit trial data to the FDA by mid-2025. Financially, Spero reported a net loss of $1.7 million for Q2 2025, with collaboration revenue from GSK contributing significantly. The company anticipates sufficient funding through 2028. Tebipenem HBr...
08-12 20:01
